|
Gene
|
Haplotype
|
Haplotype Frequencies
|
Case, Control Ratio Counts
|
Case, Control Frequencies
|
Chi Square
|
p Value
|
Odds Ratio
|
L95
|
U95
|
|---|
|
GRIK1
|
GT
|
0.073
|
6.3 : 9.7, 2.1 : 97.9
|
0.394, 0.021
|
28.362
|
1.01E-07
|
30.28
|
5.56
|
164.98
|
|
ROBO1
|
AGGT
|
0.043
|
4.1 : 7.9, 0.6 : 97.4
|
0.339, 0.006
|
28.828
|
7.91E-08
|
84.25
|
5.10
|
1391.73
|
|
SGCD
|
AAC
|
0.043
|
4.0 : 12.0, 0.9 : 99.1
|
0.251, 0.009
|
19.847
|
8.39E-06
|
36.70
|
3.45
|
390.22
|
|
PTPRD
|
TGGATCCCGT
|
0.095
|
8.3 : 7.7, 2.7 : 97.3
|
0.518, 0.027
|
38.832
|
4.62E-10
|
38.85
|
8.19
|
184.29
|
|
LPHN2
|
TTGAGCATCATCTCCCC
|
0.12
|
8.0 : 6.0, 5.0 : 89.0
|
0.571, 0.053
|
30.902
|
2.71E-08
|
23.73
|
5.91
|
95.28
|
- This table summarizes the haplotypes that were found more significantly associated with drug response than the originally identified SNP marker alone. Cell lines categorized as cases here are those which were in the resistant group and those categorized as controls are those in the sensitive group. Figure 2 illustrates the relative position of these SNP markers along the genes. Statistics with NA written indicate that the statistic could not be calculated.
